![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Newgen BioPharma Corporation (CE) | USOTC:NEWG | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.000001 | 0.00 | 01:00:00 |
Nevada
|
N/A
|
|
(State or other jurisdiction of Incorporation or organization)
|
(IRS Employer Identification No.)
|
3221 Dominquez Avenue, Quezon City, Philippines
|
(Address of principal executive offices and zip code)
|
844-624-4793
|
(Registrant’s telephone number, including area code)
|
[ ]
|
Large accelerated filer
|
[ ]
|
Accelerated filer
|
[ ]
|
Non-accelerated filer
|
☒
|
Smaller Reporting company
|
Class
|
|
Outstanding at June
[ __ ]
, 2016
|
Common stock, $0.001 par value
|
|
11,900,000
|
|
|
Page
|
|
|
|
|
|
|
Item 1.
|
4
|
|
|
|
|
Item 2.
|
12
|
|
|
|
|
Item 3.
|
15
|
|
|
|
|
Item 4.
|
15
|
|
|
|
|
|
|
|
Item 1.
|
16
|
|
|
|
|
Item 1A.
|
16
|
|
|
|
|
Item 2.
|
16
|
|
|
|
|
Item 3.
|
16
|
|
|
|
|
Item 4.
|
16
|
|
|
|
|
Item 5.
|
16
|
|
|
|
|
Item 6.
|
17
|
|
|
|
|
18
|
F - 2
|
|
F - 3
|
|
F - 4
|
|
F - 5 – F - 7
|
ASSETS
|
April 30,
2016
|
October 31,
2015
|
||||||
Current Assets
|
||||||||
Cash and cash equivalents
|
$
|
-
|
$
|
-
|
||||
Total Current Assets
|
-
|
-
|
||||||
TOTAL ASSETS
|
$
|
-
|
$
|
-
|
||||
LIABILITIES AND STOCKHOLDERS’ DEFICIT
|
||||||||
Liabilities
|
||||||||
Current Liabilities
|
||||||||
Accounts payable and accrued liabilities
|
$
|
12,562
|
$
|
13,661
|
||||
Notes payable – related party
|
88,076
|
69,644
|
||||||
Total Liabilities
|
100,638
|
83,305
|
||||||
Stockholders’ Deficit
|
||||||||
Common stock, par $0.001, 75,000,000 shares authorized, 11,900,000 shares issued and outstanding
|
11,900
|
11,900
|
||||||
Additional paid in capital
|
53,477
|
53,477
|
||||||
Accumulated deficit
|
(166,015
|
)
|
(148,682
|
)
|
||||
Total Stockholders’ Deficit
|
(100,638
|
)
|
(83,305
|
)
|
||||
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT
|
$
|
-
|
$
|
-
|
Three months ended
April 30,
2016
|
Three months ended
April 30,
2015
|
Six months ended
April 30,
2016
|
Six months ended
April 30,
2015
|
|||||||||||||
GROSS REVENUES
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
-
|
||||||||
OPERATING EXPENSES
|
||||||||||||||||
Professional fees
|
4,945
|
3,987
|
15,029
|
12,608
|
||||||||||||
General and administrative
|
1,100
|
1,400
|
2,304
|
2,954
|
||||||||||||
TOTOAL OPERATING EXPENSES
|
6,045
|
5,387
|
17,333
|
15,562
|
||||||||||||
LOSS FROM OPERATIONS
|
(6,045
|
)
|
(5,387
|
)
|
(17,333
|
)
|
(15,562
|
)
|
||||||||
OTHER EXPENSES
|
-
|
-
|
-
|
-
|
||||||||||||
NET LOSS BEFORE INCOME TAXES
|
(6,045
|
)
|
(5,387
|
)
|
(17,333
|
)
|
(15,562
|
)
|
||||||||
PROVISION FOR INCOME TAXES
|
-
|
-
|
-
|
-
|
||||||||||||
NET LOSS
|
$
|
(6,045
|
)
|
$
|
(5,387
|
)
|
$
|
(17,333
|
)
|
$
|
(15,562
|
)
|
||||
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED
|
11,900,000
|
11,900,000
|
11,900,000
|
11,900,000
|
||||||||||||
NET LOSS PER SHARE: BASIC AND DILUTED
|
$
|
(0.00
|
)
|
$
|
(0.00
|
)
|
$
|
(0.00
|
)
|
$
|
(0.00
|
)
|
Six months ended
April 30,
2016
|
Six months ended
April 30,
2015
|
|||||||
Cash Flows from Operating Activities:
|
||||||||
Net loss
|
$
|
(17,333
|
)
|
$
|
(15,562
|
)
|
||
Changes in Assets and Liabilities
|
||||||||
Increase (decrease) in accounts payable and accrued liabilities
|
(1,099
|
)
|
(2,337
|
)
|
||||
Net Cash Used in Operating Activities
|
(18,432
|
)
|
(17,899
|
)
|
||||
Cash Flows from Financing Activities:
|
||||||||
Proceeds from notes payable – related party
|
18,432
|
17,899
|
||||||
Net Cash Provided by Financing Activities
|
18,432
|
17,899
|
||||||
Net Increase (Decrease) in Cash and Cash Equivalents
|
-
|
-
|
||||||
Cash and Cash Equivalents – Beginning
|
-
|
-
|
||||||
Cash and Cash Equivalents – Ending
|
$
|
-
|
$
|
-
|
||||
Supplemental Cash Flow Information:
|
||||||||
Cash paid for interest
|
$
|
-
|
$
|
-
|
||||
Cash paid for income taxes
|
$
|
-
|
$
|
-
|
April 30,
2016
|
October 31,
2015
|
|||||||
Legal
|
$
|
9,512
|
$
|
4,861
|
||||
Audit
|
1,750
|
5,000
|
||||||
Accounting
|
1,250
|
3,750
|
||||||
Edgarizing and other
|
50
|
50
|
||||||
Total Accrued Expenses
|
$
|
12,562
|
$
|
13,661
|
(a)
|
As at January 31, 2016, the Company owed $88,076 (October 31, 2015 - $69,644) to the President and Director of the Company for loans made to the Company for working capital. The amounts owing are unsecured, non-interest bearing, and due on demand.
|
Gross Proceeds
|
$
|
100,000.00
|
||
Offering Expense
|
$
|
20,000.00
|
||
Net Proceeds
|
$
|
100,000.00
|
||
Net Proceeds to be used
|
||||
Inventory
|
$
|
40,000.00
|
||
Website development
|
$
|
5,000.00
|
||
Marketing and Advertising
|
$
|
20,000.00
|
||
Audit, Accounting and filing Fees
|
$
|
10,000.00
|
||
Working Capital
|
$
|
17,217.00
|
||
Repayment of accounts payable and accrued liabilities
|
$
|
7,783.00
|
1. | $25,000 in connection with the development of our website and marketing efforts; and |
2. | $10,000 in operating expenses, including professional legal and accounting expenses associated with our company being a reporting issuer under the Securities Exchange Act of 1934. |
Exhibit
|
|
Description
|
No.
|
|
|
3.1
|
||
3.2
|
||
31*
|
|
Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
32*
|
|
Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
101*
|
Interactive Data Files
|
|
GREENWIND NRG INC.
|
|
|
Dated: June 14, 2016
|
By:
|
/s/ Jerwin Alfiler
|
||
Name:
|
Jerwin Alfiler
|
||
Title:
|
President, Secretary, Treasurer and Director
(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
|
1 Year Newgen BioPharma (CE) Chart |
1 Month Newgen BioPharma (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions